Latest News

DANVERS, MASS. (May 30, 2012) – A member of the Scleroderma Foundation’s Board of Directors has led a team of researchers who have identified a peptide that can block fibrosis of the skin and lungs, according to a report published today. “Lung fibrosis currently is the number one cause of death in patients with scleroderma,” said the report’s senior author Carol A. Feghali-Bostwick, Ph.D.

Praises Senate for Addressing Needs of Rare Disease Patients

By Robert Pear, New York Times

May 24,2012, WASHINGTON — The Senate on Thursday passed a major bipartisan bill to prevent drug shortages and to speed federal approval of new lifesaving medicines, including lower-cost generic versions of biotechnology products.

Canadian Double-Lung Transplant Recipient Receives Diamond Jubilee Medal from Canadian Prime Minister Harper

Foundation Announces Suite of Complementary Initiatives for Patients and Caregivers to Provide Enhanced Resources and Support

The medical schools of Stony Brook University and New York University have struck an agreement with a New Jersey pharmaceutical company to develop an experimental treatment for a fatal lung disease.

FibroGen Expands Clinical Study Based on Preliminary Data Indicating Improvement in Lung Function and Lung Fibrosis in Patients with IPF